BioNTech and MediLink’s HER3 ADC Back In The Game After Safety Concerns
The partners still believe their HER3-targeting ADC can rival Merck & Co and Daiichi Sankyo’s frontrunner, even at a new lower dose range.
The partners still believe their HER3-targeting ADC can rival Merck & Co and Daiichi Sankyo’s frontrunner, even at a new lower dose range.